INTRODUCTION

Neuropathic pain (NP) is pain caused either by damage or disease that affects the somatosensory system centrally (multiple sclerosis, spinal cord injury, post-stroke, etc.) or peripherally (polyneuropathies related to diabetes, chemotherapy, alcoholism, infection, etc.) [1]. Patients suffering from neuropathy present with lancinating, shooting, and/or burning pain along with tingling sensation, which substantially impairs their quality of life [2,3]. A single etiology or specific lesion cannot explain this heterogeneous set of conditions. A multidisciplinary approach to treatment is often the most successful, which includes drugs (antidepressant and antiepileptic drugs), anesthetic techniques, and surgical interventions (in patients with refractory NP) [4,5]. Opioids have been considered a good choice for treatment; however, they fail to reduce the pain and are controversial [6]. Other drugs include acetyl-L-carnitine (ALC), alpha-lipoic-acid (ALA), cannabis products, botulinum toxin, and angiotensin type 2 receptor antagonists [5,6]. A precise treatment regimen is still not available; however, blockers of voltage-gated sodium channels and of the alpha-2-delta-1 subunit of calcium channels demonstrate a significant therapeutic potential [7,8]. Moreover, these centrally acting drugs are lipophilic and nonspecific with a narrow therapeutic window, thus restraining their prolonged use in pain management. Considering the pitfalls of conventional neuropathy treatments, a novel approach to the treatment of chronic pain is required, which would regulate the excitability of nociceptors. The importance of nociceptors, immune cells, and G protein-coupled receptors (GPCRs) is well established in the pathology of NP [2,3].

In general, new technical advancements and interdisciplinary treatment methods offer more therapeutic effectiveness. One such interdisciplinary approach is optogenetics. Optogenetics is a versatile technique in which engineers, clinicians, and basic science researchers converge their knowledge of genetics and optics to achieve gain or loss of function in specific cells of living tissue. Besides in vitro and in vivo manipulation of neuronal excitability and network activity, various optogenetic tools make it possible to target intracellular processes in particular organelles [9]. This light-sensitive technology has revolutionized the study of neuroscience with single-cell and millisecond-precision control of neurons [9] in living systems. This review article discusses the scientific landscape of the decade-old technique in NP.

BASIC CONCEPT OF OPTOGENETICS

As the name suggests, optogenetics is the integration of two fields, i.e., optics and genetics. The optic part is associated...
with illumination of a specific light spectrum, whereas the genetic part is associated with the expression of a modified opsin protein in cells. The basic concept of optogenetics is to manipulate cellular activity by transducing electrical currents generated by light-sensitive proteins [10,11]. Figure 1 shows the three major optogenetic tools, which include: 1) light-activated proteins, 2) light, and 3) mode of delivery (important for both of the first two tools).

Opsins capture light and use it to either actively pump ions across the cell membrane or to open the channels, which allows the passive flow of ions across the cell membrane. These proteins are ubiquitously present in all organisms, including eukaryotes and prokaryotes. Engineering the expression of opsins in non-light-sensitive cells enables rapid optical control of specific cellular processes. Therefore, by applying the optogenetic approach a rapid activation and silencing of expressed proteins can be achieved with no use of chemicals [9,11]. Microbial opsins, an important class of light-sensitive proteins, are categorized based on membrane potential. Channelrhodopsins (ChRs) from *Chlamydomonas reinhardtii* depolarize the neuronal membrane with light, whereas the second class of opsins, halorhodopsin from *Natronomonas pharaonis* (NpHR), causes hyperpolarization. Proton pumps such as bacteriorhodopsin, proteorhodopsin, and archaerhodopsin also promote the hyperpolarization of the neuronal membrane by extruding protons from the cytoplasm. The co-expression of depolarizing and hyperpolarizing opsins due to varying illumination patterns allows creating a bidirectional channel in cells [10,12]. Chimeric receptors that mimic various signaling cascades represent another class of light-activated opsins. These include light-activated membrane-integrated GPCRs (e.g., OptoXR) and hybrid receptors with the extracellular domain of rhodopsin and the intracellular domain of specific adrenergic receptors (AR) such as opto-α1-AR (Gq-coupled human α1A-AR) and opto-β2-AR (Gs-coupled hamster β2-AR) [10,12,13]. Properties like i) ion specificity, ii) subcellular localization, iii) sensitivity to light, iv) fast kinetics, v) possibility for bidirectional control, and vi) simple structure make opsins an ideal tool in the field of optogenetics.

The second tool in the optogenetic toolbox is the light wavelength to activate a specific opsin. The differential wavelength specificity and sensitivity of opsins allow the co-expression of different proteins in one cell and make simultaneous activation and deactivation feasible. Therefore, two different proteins can be used antagonistically or synergistically. For example, ChR2 is activated by ~460 nm light and NpHR is activated by ~570 nm light. Engineered opsins with red-shifted activation wavelengths make it easy to deliver the proteins to challenging sites, such as deep in the brain, with minimal invasiveness. Red-shifted activation wavelengths help reducing the light scattering and, therefore, allow deeper light penetration. ChRs are light-gated, non-specific cation channels, activated by blue-green wavelength from 450 nm to 545 nm [14]. Such blue-green wavelengths fail to penetrate neural tissue as they are absorbed by flavins, hemoglobin, and melanin. Furthermore, blue-green wavelengths scatter more strongly than yellow-red wavelengths. To overcome this, red-shifted ChRs with spectral peaks near or above 600 nm are engineered, which include the cation channels (activation wavelengths) as follows: red-activatable ChR (ReaChR) (~590–630); ChR1/Volvox (CiV1; E122T mutation; ChR1/VChR1 chimera) (~600 nm); Chrimson (~660 nm); fast red-activatable ChR (bReaChES) (~590 nm); Volvox ChR (VChR1; similar to ChR-1) (~531 nm), and the chloride pump jaws (~635 nm). Moreover, the ChR2 gene has been modified to produce a “ bistable ” channel also known as step-function opsin (SFO). This channel is opened by one wavelength and closed by a different wavelength [9,15].

![FIGURE 1. Flowchart of (A) experimental steps and (B) various tools in optogenetics.](image-url)
TABLE 1. Commonly used viral delivery systems in optogenetics

| Characteristic | Herpes virus | Canine virus | Lentivirus | Adeno-associated virus | Rabies virus |
|----------------|--------------|--------------|------------|------------------------|--------------|
| Family         | Herpes simplex virus | Adenovirus   | Retrovirus | Parovirus               | Rhabdovirus  |
| Genome         | dsDNA        | dsDNA        | RNA        | ssDNA                  | ssRNA        |
| Packaging capacity | ~100–150 kb | ~30–36 kb    | ~10 kb     | ~5 kb                  | ~1–3 kb      |
| Host genome integration | No           | No           | Yes        | No                     | No           |
| Cells infected | Dividing/Non-dividing | Dividing/Non-dividing | Dividing | Dividing/Non-dividing | Dividing/Non-dividing |
| Expression     | Stable       | Transient    | Stable     | Stable                 | Stable       |

ds: double-stranded; ss: single-stranded

OPTOGENETICS IN NEUROPATHY

Optogenetics offers selective activation with a millisecond temporal precision compared to electrical stimulation, which is more generalized and non-selective. Such light-sensitive cellular stimulation eliminates the crucial step of placing the electrodes in the brain that has a relatively homogeneous group of neurons [21]. Although initial in vivo studies have been performed in transgenic mouse models, most of them were restricted to in vitro preparations and were not applied to freely moving animals. In an early study, Wang and Zylka demonstrated the power of optogenetics in causal dissection of pain circuitry [22]. They showed functional connectivity in the substantia gelatinosa layer in a transgenic mouse line that expressed a stimulatory opsin in a nociceptor subtype expressing Mas-related GPCR member D [22]. In another study, Daou et al. [23] demonstrated the role of optogenetics in pain inhibition using a binary genetic approach, to deliver ChR2 channels to peripheral nociceptors in Nav1.8-Cre transgenic mouse line. In their experiment, the pain was elicited noninvasively and remotely in animals (without the implantation of optical devices) [23]. AAV serotype 6 expressing ChR protein successfully controlled NP in vivo. AAV virus has advantage compared to other vectors [24]. In vivo stimulation of yellow light-sensitive third-generation chloride pump halorhodopsin (eNpHR3.0) channel successfully prevented pain in a NP model and, therefore, highlighted the therapeutic potential of optogenetics [25,26].

The real challenge in optogenetics is to pinpoint damaged nociceptive neurons. Therefore, understanding the genetics in pathological neurons compared to normal functioning neural circuits is pertinent. A complete transcriptome of the trigeminal ganglia (TG) and the dorsal root ganglia (DRG) of adult mice has been analyzed to get an insight into the expression of ion channels and GPCRs in physiological and pathophysiological conditions [27–29]. This analysis revealed that the conventional strategies, which inhibit individual ion channels or inflammatory processes, would not be as useful given the complex etiology of pathological changes in ganglia.

Because NP affects not only patients but also their families, there is an urgent need to find the treatment. Researchers are developing alternative treatment approaches like designer
receptors exclusively activated by a designer drug (DREADD). Synthetic ligands such as clozapine N-oxide (CNO) manage NP by activating these designer receptors. Except the modulation by synthetic chemicals and not by endogenous ligands, DREADDs behave similar to endogenous GPCRs and, therefore, interact efficiently with downstream intracellular signaling components [30-32]. Due to the similarities to GPCRs, testing how DREADDs affect the GPCR downstream signaling is encouraged.

The light-sensitive proteins are generally introduced to targeted mammalian neurons using viral gene delivery approaches [12,33]. However, the limitations of the viral vector delivery system in humans are well known [33,34]. A newer noninvasive technology, transcranial FUS, targets the BBB by systemic injection of lipid-based microbubbles (a mixture composed of ultrasound contrast agents) containing molecules of interest [17,35,36]. Considering the noninvasive nature of the FUS technique, viral vectors encoding various light-activated protein channels can be delivered in vivo, allowing an entirely noninvasive neural stimulation.

Optogenetics allows us to manipulate and monitor the neuronal circuit functions, and it has been successfully implicated in behavioral studies including sensory perception [31], pain [37], and social interactions [38]. A recent advancement in optogenetics has revealed that specific components of higher brain functions can neither be linked to single transmitter systems nor to specific brain locations [1,39], suggesting that a multitasking optogenetic sensor has to be designed. With these advancements in the field of optogenetics and promising results from recent experiments in non-human primates [40,41], we anticipate that the therapeutic application of optogenetics will be available in clinics soon.

Spatially targeted, genetic strategies for sustained inhibition of nociceptors are an example of the translation of laboratory research into the clinic. A recent report demonstrated the advantage of a step-function inhibitory ChR, named SwiChR, over the normal ChR by overcoming the required constant illumination [26]. SwiChR inhibits pain for long periods of time with infrequent transdermal delivered light pulses, reducing the required light exposure by >98% and, therefore, resolving a long-standing limitation in optogenetic inhibition [26,37,38].

OPTOGENETICS: BEYOND NEUROSCIENCE

Although first introduced in neuroscience, optogenetics has been applied to other fields as well, including cardiovascular research, cancer research, and hepatology. Recent developments in stem cell research demonstrate a potential of a combined approach for the treatment of different diseases. The approach combining optogenetics and stem cells has opened up treatment strategies for neurodegenerative and cardiovascular diseases. Engineered stem cells expressing exogenous light-activated opsins have been used in recent years. A functional analysis of human embryonic stem cells (ESC)-derived neurons in a Parkinson's disease mouse model that was implanted with a fiber-optic cannula revealed that light induces selective silencing of transplanted neurons in mice [42]. Bruegmann et al. demonstrated the induction of optically derived currents using genetically modified mouse ESC-derived cardiomyocytes expressing ChR2 variant [43]. Some of the studies have also used hESC for the activation of cardiomyocytes by optogenetics [44,45]. In addition, optogenetics has been widely studied in other research fields such as diabetes research [46], immunotherapy [47], retinal gene therapy, and ophthalmology [48].

CONCLUDING REMARKS AND FUTURE PROSPECTIVE

Chronic pain is one of the major health issues worldwide. Besides affecting the patient’s functionality, it also impacts the patient's family; therefore, the treatment of such disorders would be beneficial for both. Selective targeting of neuronal systems enables the inhibition of chronic pain. Future studies should aim to delineate the influence of an individual’s genotype on the predisposition to pain chronicity and the response to therapeutic treatments, considering that the sensitivity to painful stimuli and the response to drugs vary from one person to another. In addition, a better understanding of epigenetic regulation of the disease could also lead to innovations and, therefore, should be among the major focuses of future therapeutic approaches.

Although optogenetics is an exciting approach for future treatment of chronic pain, there are still many unanswered questions. For example, it is not clear if the treatment with light will be short-term or long-term? Furthermore, what would be the appropriate treatment regimen in terms of dosage? Another concern is what the route of administration would be and how light-sensitive proteins will be introduced in human subjects. As stated earlier, the major obstacle is the controlled delivery of light to cells; however, recent studies have shown some progress in combating this problem, using microscopy-based cell analyses and flow cytometry [16,49]. Another powerful approach represents a technique that combines optogenetics and the clustered regularly interspaced short palindromic repeats (CRISPR)—Cas system. These technologies will facilitate testing of optogenetic tools in various cellular models to attain a proof of principle.

RetroSense Therapeutics (now acquired by Allergan) delivered the first-in-human optogenetic therapy for advanced retinitis pigmentosa, which was followed by RPE65 rAAV by Spark therapeutics, an FDA-approved therapy for retinal
dystrophy in December 2017 [50]. In such conditions, photoreceptors in the retina gradually die off, which eventually leads to blindness. The RetroSense therapy RST-001 delivers an adenoassociated virus virus containing the ChR2 gene in the eye of patients to create new photoreceptors in retinal cells. This clinical trial is in Phase I/II and is still enrolling the subjects (https://clinicaltrials.gov/ct2/home). Till date, no results have been revealed from this clinical trial. The exact type of vision which will be generated by modified retinal cells remains unclear because a diverse group of retinal ganglion cells are stimulated.

Gensight Biologics (https://www.gensight-biologics.com) designed a “biomimetic goggles,” which consist of a camera, microprocessor, and a digital micromirror array. This device stimulates the modified retinal cells by amplifying light signals. The company has recently treated the first subject in the first-in-man PIONEER Phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. GS030 combines a gene therapy (GS030-DP) administered through a single intravitreal injection with a wearable optronic visual stimulation device [GS030-MD] (https://www.gensight-biologics.com). The final results of this study are expected in the fourth quarter of 2020. In addition to this, Gensight Biologics is developing a treatment for geographic atrophy in dry age-related macular degeneration (AMD) using the optogenetics approach. Companies like Circuit Therapeutics (http://www.circuittx.com) and Bionic Sight (https://agtc.com/programs/bionic-sight/) are also developing new optogenetic strategies to understand the cause and treat different neurological diseases. Recently, optoPAIN, an optogenetic platform to noninvasively assess changes in pain sensitivity, has been developed and used to examine pharmacological and chemogenetic inhibition of pain [48]. Such techniques and developments hold the promise to see optogenetics in clinical setting in the near future [51,52].

The pathophysiology of NP remains enigmatic. Structural modifications and activation of nociceptors in neurons generate a high action potential and transmit signals through already existing pain transmission network. Using optogenetic tools, neuronal circuit function can be manipulated and monitored, and therefore, a therapeutic approach combining optogenetics and gene therapy can be explored in the near future.

ACKNOWLEDGMENTS

We would like to thank Science Pen Group for helping in proofreading the article.

DECLARATION OF INTERESTS

The authors declare no conflict of interests.

REFERENCES

[1] Song C, Knöpfel T. Optogenetics enlightens neuroscience drug discovery. Nat Rev Drug Discov 2016;15:537-109. https://doi.org/10.1038/nrd.2015.15.
[2] Baron R. Mechanisms of disease: Neuropathic pain - a clinical perspective. Nat Clin Pract Neurol 2006;2:95-106. https://doi.org/10.1038/ncpneuro0013.
[3] Cohen SP, Mao J. Neuropathic pain: Mechanisms and their clinical implications. BMJ 2014;348:f7656. https://doi.org/10.1136/bmj.f7656.
[4] Pessoa BL, Escudeiro G, Nascimento OI. Emerging treatments for neuropathic pain. Curr Pain Headache Rep 2015;19:836. https://doi.org/10.1007/s11916-015-0519-2.
[5] Schestatsky P, Vidor L, Wünckler PB, Araújo TG, Caumo W. Promising treatments for neuropathic pain. Arq Neuropsiquiatr 2014;72:881-8. https://doi.org/10.1590/0004-282X20140157.
[6] Finnerup NB, Atal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14:662-73. https://doi.org/10.1016/S1474-4422(14)70251-0.
[7] Siczukidlik A, Dobrogowska J, Woddiezcz J, Stepien A, Krajnik M, Leppert W, et al. Diagnosis and management of neuropathic pain: Review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society part one. Neurol Neurochir Pol 2014;48:626-71. https://doi.org/10.1515/npms.2014.01101.
[8] Nascimento OJ, Pessoa BL, Orsini M, Ribeiro P, Davidovich E, Pupe C, et al. Neuropathic pain treatment: Still a challenge. Neurol Int 2016;8:632. https://doi.org/10.1081/ni.20016322.
[9] Rost BR, Schneider-Warne F, Schmitz D, Hegemann P. Optogenetic tools for subcellular applications in neuroscience. Neuron 2017;96:572-603. https://doi.org/10.1016/j.neuron.2017.09.047.
[10] Berndt A, Lee SY, Wietek J, Ramakrishnan C, Steinberg EE, Rashid AI, et al. Structural foundations of optogenetics: Determinants of channelrhodopsin ion selectivity. Proc Natl Acad Sci U S A 2016;113:822-9. https://doi.org/10.1073/pnas.1523341113.
[11] Boyden ES. Optogenetics and the future of neuroscience. Nat Neurosci 2015;18:1200-1. https://doi.org/10.1038/nn.4094;
[12] Zhang F, Vierock J, Yizhar O, Fenno LE, Tsunoda S, Steinberg EE, et al. Independent optical excitation of distinct neural membrane channel. Proc Natl Acad Sci U S A 2003;100:13940-5. https://doi.org/10.1073/pnas.1523341113.
[13] Nascimento OJ, Pessoa BL, Orsini M, Ribeiro P, Davidovich E, Pupe C, et al. Neuropathic pain treatment: Still a challenge. Neurol Int 2016;8:632. https://doi.org/10.1081/ni.20016322.
[14] Zhang F, Vierock J, Yizhar O, Fenno LE, Tsunoda S, Steinberg EE, et al. Independent optical excitation of distinct neural membrane channel. Proc Natl Acad Sci U S A 2003;100:13940-5. https://doi.org/10.1073/pnas.1523341113.
[15] Klapoetke NC, Murata Y, Kim SS, Pulver SR, Birdsey-Benson A, Cho YK, et al. Independent optical excitation of distinct neural populations. Nat Methods 2014;11:338-46. https://doi.org/10.1038/nmeth.2836.
[16] Wang J, Tang S, Wan Z, Gao Y, Cao Y, Yi J, et al. Utilization of a photocatable antigen system to examine B-cell probing termination and the B-cell receptor sorting mechanisms during B-cell activation. Proc Natl Acad Sci U S A 2016;113:E558-67. https://doi.org/10.1073/pnas.1517612113.
[17] Wang S, Kugelman T, Bach A, Herman M, Han Y, Karakatsani ME, et al. Non-invasive, focused ultrasound-facilitated gene delivery for optogenetics. Sci Rep 2017;7:39955. https://doi.org/10.1038/srep39955.

[18] Scharf R, Tsunematsu T, McAlinden N, Dawson MD, Sakata S, Matheson K, et al. Depth-specific optogenetic control in vivo with a scalable, high-density µLED neural probe. Sci Rep 2016;6:28381. https://doi.org/10.1038/srep28381.

[19] Szabo V, Ventalon C, De Sars V, Bradley J, Emiliiani V. Spatially selective holographic photostimulation and functional fluorescence imaging in freely behaving mice with a fibroscope. Neuron 2014;84:157-69. https://doi.org/10.1016/j.neuron.2014.11.005.

[20] Gagnon-Turcotte G, LeChasseur Y, Bories C, Messaddeq Y, De Koninck Y, Gosselin B, et al. A wireless headstage for combined optogenetics and multifrequency electrophysiological recording. IEEE Trans Biomed Circuits Syst 2017;11:7-14. https://doi.org/10.1109/TBCAS.2016.257864.

[21] Gui L, Ubedzki ML, Anand S, Romero-Ortega M, Kim YT, Fuchs PN, et al. Pain inhibition by optogenetic activation of specific anterior cingulate cortical neurons. PLoS One 2015;10:e0117746. https://doi.org/10.1371/journal.pone.0117746.

[22] Wang H, Zylka MJ. Mrgrd-expressing polymodal nociceptive neurons innervate most known classes of substantia gelatinosa neurons. J Neurosci 2009;29:12027-39. https://doi.org/10.1523/JNEUROSCI.1248-09.2009.

[23] Daou I, Tuttle AH, Longo G, Wieskopf JS, Bonin RP, Ase AR, et al. Remote optogenetic activation and sensitization of pain pathways in freely moving mice. J Neurosci 2013;33:18631-40. https://doi.org/10.1523/JNEUROSCI.2442-13.2013.

[24] Lee GH, Kim SS. Therapeutic strategies for neuropathic pain: Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain 2009;5:52. https://doi.org/10.1186/1744-8069-5-52.

[25] Iyer SM, Vesuna S, Ramakrishnan C, Huynh K, Young S, Berndt A, et al. Potential application of pharmacosynthetics and optogenetics. Mediators Inflamm 2016;2016:3808215. https://doi.org/10.1155/2016/3808215.

[26] Towne C, Pertin M, Begga AT, Aebischer P, Decosterd I. Activation of specific interneurons improves responses to frontoparietal and rhinal cortex reversibly disrupts reward value. Nat Neurosci 2016;19:401-2. https://doi.org/10.1038/nn.4192.

[27] Lammel S, Tye KM, Warden MR. Progress in understanding mood disorders: Optogenetic dissection of neural circuits. Genes Brain Behav 2014;13:38-51. https://doi.org/10.1111/gbb.12019.

[28] Steinbeck JA, Choi SJ, Mjeuru A, Ganat Y, Deisseroth K, Sulzer D, et al. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson’s disease model. Nat Biotechnol 2015;33:204-9. https://doi.org/10.1038/nbt.3124.

[29] Koninck Y, Gosselin B, et al. A wireless headstage for combined fluorescence imaging in freely behaving mice with a fiberscope. Neuron 2012;488:379-83. https://doi.org/10.1038/nature11312.

[30] Urban DJ, Roth BL. DREADDs (designer receptors exclusively activated by designer drugs): Chemogenetic tools with therapeutic utility. Annu Rev Pharmacol Toxicol 2015;55:399-417. https://doi.org/10.1146/annurev-pharmaco-031814-124803.

[31] Parr-Brownlie LC, Bosch-Boujui C, Schoderbock L, Szemere RJ, Abraham WC, Hughes SM, et al. Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. Front Mol Neurosci 2015;8:14. https://doi.org/10.3389/fnmol.2015.00014.

[32] Szemere RJ, Seeger-Arnbruster S, Hughes SM, Parr-Brownlie LC. Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology. J Neurophysiol 2016;115:2124-46. https://doi.org/10.1123/jn.001131.2015.

[33] Choi HJ, Selet K, Vlacov F, Wong A, Konofagou EE. Noninvasive and localized neuronal delivery using short ultrasonic pulses and microbubbles. Proc Natl Acad Sci U S A 2011;108:16539-44. https://doi.org/10.1073/pnas.1015160108.

[34] O’Reilly MA, Waspe AC, Ganguly M, Hynynen K. Focused-ultrasound disruption of the blood-brain barrier using closely-timed short pulses: Influence of sonication parameters and injection rate. Ultrasound Med Biol 2013;37:87-94. https://doi.org/10.1016/j.ultrasmedbio.2011.01.008.

[35] Iyer SM, Montgomery KL, Towne C, Lee SY, Ramakrishnan C, Deisseroth K, et al. Virally mediated optogenetic excitation and inhibition of pain in freely moving nontransgenic mice. Nat Biotechnol 2014;32:274-8. https://doi.org/10.1038/nbt.3083.

[36] Albo AP, Vander Weele CM, Wichmann R, Tye KM. Optogenetic insights on the relationship between anxiety-related behaviors and social deficits. Front Behav Neurosci 2014;8:241. https://doi.org/10.3389/fnbeh.2014.00241.

[37] Sorge RE, Martin LJ, Ibska B, Sotocinal SG, Rosen S, Tuttle AH, et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods 2014;11:629-32. https://doi.org/10.1038/nmeth.2935.

[38] Budzikova D, Bucan M, Le Cuona MC, Vishnevskaya EV, Myasnikov AV, et al. Remote optogenetic control of heart muscle in vitro and in vivo. Methods 2014;63:797-807. https://doi.org/10.1016/j.ymeth.2014.11.012.

[39] Liu H, Zhang Y, Sun W, Jiang X, Liu W, et al. Remote optogenetic control of heart muscle in vitro and in vivo. Methods 2014;63:797-807. https://doi.org/10.1016/j.ymeth.2014.11.012.

[40] Nussinovitch U, Geppstein L. Optogenetics for in vivo cardiac pacing and resynchronization therapies. Nat Biotechnol 2015;33:759-40. https://doi.org/10.1038/nbt.3268.

[41] Nussinovitch U, Shamravi R, Geppstein L. Modulation of cardiac tissue electrophysiological properties with light-sensitive proteins. Cardiovasc Res 2014;102:176-87. https://doi.org/10.1093/cvr/cvt037.

[42] Kushibiki T, Okawa S, Hirasawa T, Ishihara M. Optogenetic control of heart muscle in vitro and in vivo. Neurology 2013;81:164-7. https://doi.org/10.1212/WNL.0b013e3182c6e6f6.

[43] Xu Y, Hyun YM, Lim K, Lee H, Cummings RJ, Gerber SA, et al. Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci U S A 2012;109:13177-82. https://doi.org/10.1073/pnas.1213177109.

[44] Jacobson SG, Sumaroka A, Luo X, Cideciyan AV. Retinal optogenetic therapies: Clinical criteria for candidacy. Clin Genet 2013;84:175-82. https://doi.org/10.1111/cge.12165.
[49] Brenker K, Osthof K, Yang J, Roth M. LED thermo flow - combining optogenetics with flow cytometry. J Vis Exp 2016;118:e54707. https://doi.org/10.3791/54707.

[50] Maimon BE, Diaz M, Revol ECM, Schneider AM, Leaker B, Varela CE, et al. Optogenetic peripheral nerve immunogenicity. Sci Rep 2018;8:14076. https://doi.org/10.1038/s41598-018-32075-0.

[51] Mukerjee S, Lazartigues E. Next-generation tools to study autonomic regulation in vivo. Neurosci Bull 2019;35:113-23. https://doi.org/10.1007/s12264-018-0319-2.

[52] Song YH, Agrawal NK, Griffin JM, Schmidt CE. Recent advances in nanotherapeutic strategies for spinal cord injury repair. Adv Drug Deliv Rev 2018;12:30-15. https://doi.org/10.1016/j.addr.2018.12.011.

Related articles published in BJBMS

1. Hyperalgesia-type response reveals no difference in pain-related behavior between Wistar and Sprague-Dawley Rats
   Katarina Vukojević et al., BJBMS, 2007

2. Laser therapy of painful shoulder and shoulder-hand syndrome in treatment of patients after the stroke
   Azra Karabegović et al., BJBMS, 2009